Business Wire

Automotive Industry Adopts GSMA Embedded SIM Specification to Accelerate Connected Car Market

Del

Leading companies from across the automotive and transportation sector are supporting the GSMA Embedded SIM Specification to help accelerate the growth of the connected car market, the GSMA announced today. The interoperable specification has been backed by international brands including General Motors, Jaguar Land Rover, Renault Nissan, Scania and Volvo Cars, and will enable automakers to remotely provision connectivity over the air to vehicles with an operator of their choice. It will help to deliver a range of in-vehicle services such as infotainment, real-time navigation, insurance and breakdown services, as well as telematics and remote diagnostics. The use of the specification will also help to quickly connect vehicles with local operators, regardless of where the cars are manufactured.

“The GSMA Embedded SIM Specification has progressed from the first availability of commercial solutions to industry adoption in a very short space of time. The automotive sector is set for huge growth and it is clear that a common, global standard will help mobile operators to provide scalable, reliable and secure connectivity to vehicles regardless of location,” said Alex Sinclair, Chief Technology Officer, GSMA. “This approach will help car manufacturers offer any type of in-car connected service through a single SIM, which can be provisioned with the profile of a mobile operator once the car is shipped, as well as at the end of a contract, without the SIM needing to be changed.”

The connected car market is set for exponential growth. Gartner Research has forecast that one in five vehicles will have some form of wireless network connection by 2020, equating to more than 250 million connected vehicles in service¹. Additionally, Machina Research estimates that the total number of connections in the connected car market will grow at a CAGR of 31 per cent from 182 million in 2015 to 693 million in 2020.² Analyst house Berg Insight also notes that in-vehicle embedded telematics systems shipped 1.9 million units in 2014, a figure that is expected to reach 15 million by 20203.

“Jaguar Land Rover is putting connectivity at the heart of its vehicles to deliver a range of safety, security, convenience and infotainment features for our customers. The GSMA Embedded SIM Specification allows Jaguar Land Rover to reduce manufacturing complexity, adapt to changing regulatory frameworks and work with the best mobile operators, on a country-specific or regional basis, improving the customer offering to deliver the next generation of connected services over the lifetime of our vehicles,” commented Mike Bell, Global Connected Car Director, Jaguar Land Rover.

“The GSMA Embedded SIM Specification solves a number of fundamental issues in auto manufacturing principally in-market localisation and lifecycle management that enable us to provide an efficient, robust and global product,” said Fredrik Callenryd, Senior Business Strategy Manager, Scania CV AB.

“The Renault – Nissan Alliance is a global industry innovator for technology for mainstream and mass-market consumers. Supporting the GSMA Embedded SIM Specification will help sustain our innovations by enforcing a reliable and stabilized solution and enable us to offer more flexible and agile solutions. We will be able to offer our customers ease of use and a high quality of service which are Renault – Nissan’s main objectives,” commented Alexandre Corjon, Renault-Nissan Alliance Global VP, Electrics Electronics & Systems Engineering.

To date, 22 mobile operators worldwide have commercially launched solutions based on the GSMA Embedded SIM Specification. New operators to launch commercial solutions include AIS, América Móvil, KPN, MTN, Rogers Wireless, Swisscom, Taiwan Mobile, Telenor, TIM as well as members of the Bridge Alliance and the Global M2M Association. The adoption of an interoperable specification will reduce fragmentation and help the industry to take advantage of the Internet of Things, an addressable market estimated to be worth US$1.1 trillion by 2020 according to Machina Research4. Bell Canada, Deutsche Telekom, Etisalat, Indosat, NTT DOCOMO, Orange, Tele2, Telefónica Brasil, Telefónica Group, TeliaSonera and Vodafone have already made commercial solutions available to the market.

GSMA Intelligence research highlights that 76 per cent of global M2M connections are now serviced by mobile operators that are deploying or are committed to the GSMA solution, underscoring the momentum behind the specification.5 For more information on the GSMA’s Embedded SIM please go to: http://www.gsma.com/connectedliving/connected-living-mobilising-the-internet-of-things/.

GSMA Connected Living Programme at Mobile World Congress 2016

The GSMA’s Connected Living Programme will showcase the GSMA Embedded SIM Specification at Mobile World Congress 22-25 February in Barcelona. There will be a number of live demonstrations of the specification in the GSMA Innovation City located at Stands 3A11 and 3A31 in Hall 3, Fira Gran Via, including scenarios from Bridge Alliance and the Global M2M Association. There will also be a number of workshops, seminars and presentations highlighting the impact of the GSMA Embedded SIM Specification on the international market. The GSMA Innovation City will be open during Mobile World Congress exhibition hours. For further information on Mobile World Congress 2016, visit www.mobileworldcongress.com.

-ENDS-

Notes to Editors

1.) Gartner http://www.gartner.com/newsroom/id/2970017

2.) Machina Research (https://machinaresearch.com/)

3.) Berg Insight: The Global Automotive OEM Telematics Market M2M Research Series 2015 (www.berginsight.com)

4.) Machina Research (https://machinaresearch.com/)

5.) According to GSMA Intelligence, as of Q4 2015, there are 313 million cellular M2M connections for all operators committed to launching the GSMA Embedded SIM Specification accounting for 76% of total global cellular M2M connections.

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 250 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Charlie Meredith-Hardy
+44 7917 298428
CMeredith-Hardy@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom